Skip to main content

Table 1 Baseline characteristics of patients with isolated pulmonary Candida spp. colonization (cohort 1)

From: Antifungal therapy in patients with pulmonary Candida spp. colonization may have no beneficial effects

 

Antifungal therapy (n = 102)

No antifungal therapy (n = 220)

p value

Age (years)

69 (57; 76)

70 (58/78)

0.354

Sex male, n (%)

83 (81.4)

162 (73.6)

0.16

Discipline, n (%)

   

 Thoracic and cardiovascular surgery

52 (50.1)

90 (40.9)

0.093

 General and visceral surgery

12 (11.8)

33 (15.0)

0.493

 Trauma surgery

9 (8.8)

29 (13.2)

0.353

 Vascular surgery

12 (11.8)

25 (11.4)

1

 Urology

3 (2.9)

1 (0.5)

0.096

 Otolaryngology

0 (0)

5 (2.3)

0.183

 Pneumology

3 (2.9)

4 (1.8)

0.683

 Oral and maxillofacial surgery

0 (0)

4 (1.8)

0.311

 Neurosurgery

3 (2.9)

20 (9.1)

0.061

 Others

8 (7.8)

9 (4.1)

0.184

Cancer, n (%)

14 (13.7)

42 (19.1)

0.271

Permanent pacemaker, n (%)

15 (14.7)

17 (7.7)

0.071

SAPS II

47 (39; 55)

40 (30; 48)

<0.001

SOFA score

7 (5; 10)

4.5 (2; 8)

<0.001

 Lung

2 (1; 2)

1 (1; 2)

0.437

 Thrombocytes

1 (0; 2)

0 (0; 2)

0.015

 Liver

0 (0; 2)

0 (0; 0)

<0.001

 Cardiovascular

3 (0; 4)

0 (0; 3)

0.001

 Renal

1 (0; 2)

0 (0; 2)

0.017

Pre-existing pneumonia before enrollment, n (%)

58 (56.9)

89 (40.5)

0.008

  1. Data are presented as median (25 %; 75 % quartile)
  2. SAPS II Simplified Acute Physiology Score II, SOFA Sequential Organ Failure Assessment